Mesenchymal stem cell therapy for heart failure: a meta-analysis.

Area of Science:

• Cardiology
• Regenerative Medicine
• Stem Cell Therapy

Background:

• Mesenchymal stem cell (MSC) therapy is being explored as an adjunct treatment for heart failure.
• The established efficacy of MSC treatment for heart failure requires further investigation.

Purpose of the Study:

• To systematically review and meta-analyze the efficacy of MSC treatment in patients with heart failure.
• To evaluate the impact of MSC therapy on cardiac function, mortality, and rehospitalization rates.

Main Methods:

• A systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials was conducted.
• Randomized controlled trials (RCTs) comparing MSC treatment with control interventions in heart failure patients were included.
• Data extraction and quality assessment were performed by two independent investigators, with meta-analysis conducted using appropriate models.

Main Results:

• Six RCTs involving 625 patients were analyzed.
• MSC treatment significantly increased left ventricular ejection fraction (LVEF) by 9.64% (p < 0.00001) and reduced rehospitalization rates (RR = 0.41, p = 0.003).
• No significant differences were observed in cardiovascular death, myocardial infarction, heart failure recurrence, or total death between MSC treatment and control groups.

Conclusions:

• MSC treatment demonstrates a significant benefit in improving cardiac function (LVEF) and reducing rehospitalization in heart failure patients.
• Current evidence suggests MSC therapy does not significantly affect major adverse cardiovascular outcomes, including death and myocardial infarction.